Walter J. Thomsen

Proteo, Inc., a clinical stage drug development company, intends to develop, promote, and market pharmaceuticals and other biotech products. The firm focuses on the development of anti-inflammatory treatments for rare diseases. Its proprietary product Elafin, a human protein that naturally occurs in human skin, lungs, and mammary glands. The company's product is intended for the treatment of post-surgery damage to tissue, pulmonary hypertension, serious injuries caused by accidents, cardiac infarction, and other diseases, as well as for the complications resulting from organ transplantation. It has a license and collaboration agreement with ARTES Biotechnology GmbH to produce Elafin by using the sublicensed yeast HANSENULA POLYMORPHA. The company was founded by Oliver Wiedow and Birge Bargmann on December 18, 1992 and is headquartered in Irvine, CA.

bionamics GmbH was an asset management. It used to acquire or license assets in the pre-clinical phase, redirect some as assets for new and appropriate customers or develops these into the clinics, and commercializes the projects into the pharma and biotech industry. The firm offers represent a unique project based investment opportunity. It identifies and evaluates projects from academia, biotech and pharmaceutical companies. The company was headquartered in Kiel, Germany.

Part of Soex Textil-Vermarktungs GmbH, SOEX Processing Germany GmbH supplies used materials and residues. The company is based in Bitterfeld-Wolfen, Germany. The CEOs are Walter J. Thomsen, Markus Naumann, Peters Martin. The German company was founded in 1999.